BACKGROUND: The Ewing sarcoma (ES) group of tumors commonly have the t(11;22)(q24;q12) or other rearrangements involving 22q12. In addition to these consistent aberrations, both numeric and structural aberrations have been reported: namely gains of chromosomes 8 and 12, the unbalanced translocation t(1;16), and deletions at the short arm of chromosome 1. METHODS: To evaluate the frequency and to study the prognostic implications of some of these aberrations in children, the authors performed a pilot study of 26 ES pediatric patients by classic cytogenetics and/or interphase fluorescence in situ hybridization (FISH) and compared these data with clinical parameters. RESULTS: Gains of chromosomes 8 and 12 were detected, by interphase FISH, in 48% (10 of 21) and 38% (6 of 16) of the tumors, respectively, and this was not significant with respect to treatment response. Statistical analysis revealed that the presence of additional secondary structural chromosomal aberrations was associated with an unfavorable outcome (P = 0.0034 as an independent prognostic value as an unfavorable marker). Presence of metastasis at diagnosis also was found to be associated with poor outcome (P = 0.0131). Spectral karyotyping analysis was shown to facilitate the detection of more complex structural chromosomal aberrations in a representative ES tumor. CONCLUSIONS: It is important to determine whether additional structural chromosomal aberrations are present in ES tumors because it appears that a more complex karyotype with multiple chromosomal aberrations is associated with poor outcome in ES. Copyright 2001 American Cancer Society.
BACKGROUND: The Ewing sarcoma (ES) group of tumors commonly have the t(11;22)(q24;q12) or other rearrangements involving 22q12. In addition to these consistent aberrations, both numeric and structural aberrations have been reported: namely gains of chromosomes 8 and 12, the unbalanced translocation t(1;16), and deletions at the short arm of chromosome 1. METHODS: To evaluate the frequency and to study the prognostic implications of some of these aberrations in children, the authors performed a pilot study of 26 ES pediatric patients by classic cytogenetics and/or interphase fluorescence in situ hybridization (FISH) and compared these data with clinical parameters. RESULTS: Gains of chromosomes 8 and 12 were detected, by interphase FISH, in 48% (10 of 21) and 38% (6 of 16) of the tumors, respectively, and this was not significant with respect to treatment response. Statistical analysis revealed that the presence of additional secondary structural chromosomal aberrations was associated with an unfavorable outcome (P = 0.0034 as an independent prognostic value as an unfavorable marker). Presence of metastasis at diagnosis also was found to be associated with poor outcome (P = 0.0131). Spectral karyotyping analysis was shown to facilitate the detection of more complex structural chromosomal aberrations in a representative ES tumor. CONCLUSIONS: It is important to determine whether additional structural chromosomal aberrations are present in ES tumors because it appears that a more complex karyotype with multiple chromosomal aberrations is associated with poor outcome in ES. Copyright 2001 American Cancer Society.
Authors: Mona S Jahromi; Angelica R Putnam; Colleen Druzgal; Jennifer Wright; Holly Spraker-Perlman; Michelle Kinsey; Holly Zhou; Kenneth M Boucher; R Lor Randall; Kevin B Jones; David Lucas; Andrew Rosenberg; Dafydd Thomas; Stephen L Lessnick; Joshua D Schiffman Journal: Cancer Genet Date: 2012 Jul-Aug
Authors: Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor Journal: Front Oncol Date: 2013-06-06 Impact factor: 6.244
Authors: Suvi Savola; Arto Klami; Abhishek Tripathi; Tarja Niini; Massimo Serra; Piero Picci; Samuel Kaski; Diana Zambelli; Katia Scotlandi; Sakari Knuutila Journal: BMC Cancer Date: 2009-01-14 Impact factor: 4.430
Authors: C M Hattinger; U Pötschger; M Tarkkanen; J Squire; M Zielenska; S Kiuru-Kuhlefelt; L Kager; P Thorner; S Knuutila; F K Niggli; P F Ambros; H Gadner; D R Betts Journal: Br J Cancer Date: 2002-06-05 Impact factor: 7.640